Celltrion announced on September 4 that it recently received marketing authorization for its Avastin biosimilar Vegzelma (ingredient name: bevacizumab) from the Australian Therapeutic Goods Administration.
Celltrion has received marketing authorization for Vegzelma in Australia for the full label approved for Avastin, including metastatic colorectal cancer, non-small cell lung cancer, metastatic renal cell carcinoma, cervical cancer, epithelial ovarian cancer, fallopian tube cancer, primary peritoneal cancer and glioblastoma.
This approval will bring Celltrion's total number of commercialized products in Oceania to six, further strengthening its presence and competitiveness on the continent. Australia, in particular, is a leading biosimilar-friendly country, actively promoting biosimilar prescribing and policy support.
Celltrion has been gradually expanding its presence in Australia since 2015 with the approval of six products, including Ramsima for autoimmune diseases, Truxima for blood cancer, Herzuma for breast and gastric cancer, Ramsima SC for autoimmune diseases, and Vegzelma for metastatic colorectal cancer.
The approval of Vegzelma, in particular, adds to a strong portfolio of anti-cancer antibody therapies, alongside earlier advances in Herzuma and Truxima.
Celltrion is actively preparing to expand its share of the bevacizumab market with the approval of Vegzelma in Australia and other key countries around the world.
Including Australia, Vegzelma is now approved in 39 countries across the U.S., Europe, the U.K., Japan and South Korea.
According to IQVIA, a global pharmaceutical market research organization, the global Vegzelma market is expected to reach $5.61 billion in 2022.
